QNCX Q3 EPS Estimate Lifted by Brookline Capital Management

Key Points

• Brookline Capital Management has raised their Q3 2025 earnings per share estimate for Quince Therapeutics from ($0.25) to ($0.19).
• Citigroup and Citizens JMP issued new ratings for Quince Therapeutics, with Citigroup giving an "outperform" rating and Citizens JMP assigning a "strong-buy" rating with a $9.00 price target.
• Quince Therapeutics' recent earnings report revealed a loss of ($0.34) EPS, which missed the consensus estimate of ($0.28) by ($0.06).

Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Research analysts at Brookline Capital Management raised their Q3 2025 earnings per share estimates for Quince Therapeutics in a research report issued on Tuesday, August 12th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of ($0.19) per share for the quarter, up from their previous estimate of ($0.25). The consensus estimate for Quince Therapeutics' current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics' Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.04) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at $0.15 EPS.

A number of other analysts also recently weighed in on the company. Citigroup started coverage on Quince Therapeutics in a report on Tuesday, August 5th. They issued an "outperform" rating for the company. Wall Street Zen downgraded Quince Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Citizens Jmp initiated coverage on Quince Therapeutics in a research note on Tuesday, August 5th. They issued a "strong-buy" rating and a $9.00 price objective on the stock. JMP Securities decreased their target price on shares of Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating for the company in a research report on Tuesday. Finally, D. Boral Capital restated a "buy" rating and set a $4.00 price target on shares of Quince Therapeutics in a report on Friday. One analyst has rated the stock with a sell rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $8.14.

Quince Therapeutics Price Performance

QNCX stock opened at $1.68 on Friday. The company has a market capitalization of $90.23 million, a P/E ratio of -1.54 and a beta of 1.02. The company has a fifty day moving average price of $1.60 and a 200-day moving average price of $1.37. The company has a debt-to-equity ratio of 1.45, a quick ratio of 4.05 and a current ratio of 5.00. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06).

Institutional Trading of Quince Therapeutics

Hedge funds have recently modified their holdings of the stock. Two Sigma Investments LP bought a new position in Quince Therapeutics during the fourth quarter worth $57,000. Northern Trust Corp raised its holdings in shares of Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after purchasing an additional 16,501 shares during the period. Geode Capital Management LLC raised its holdings in shares of Quince Therapeutics by 10.9% during the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock valued at $703,000 after purchasing an additional 36,807 shares during the period. Shay Capital LLC boosted its position in shares of Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after purchasing an additional 104,616 shares in the last quarter. Finally, Intellectus Partners LLC acquired a new stake in shares of Quince Therapeutics in the 1st quarter valued at about $71,000. Institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.